Prescribing information


Facilitate monitoring of KISQALI▼ with the Your Choice programme 

The Your Choice programme can help facilitate monitoring of KISQALI patients in day-to-day practice: 

  • Monitor your patients in the COMFORT of their home 
  • CONFIDENCE in a service tailored to your needs 
  • Reduce COST through fewer hospital visits 

Patients enrolled onto Your Choice with KISQALI will be assigned a dedicated nurse who will provide support to complement and enhance existing support from their NHS clinical team. Assistance is offered with monitoring.

This programme is offered for the first 6 months of treatment when support may be required the most, and it may be extended beyond on a case-by-case basis. In addition, the monitoring support will be provided at a location that is convenient for your patient, i.e. at home or work.  



Benefits for you and your patients 

For you: alleviates pressures during clinic by taking bloods and performing ECG assessments outside of hospital appointments 

For your patients: reduces logistical challenges so patients may not have to come to clinic as often or for as long 

Flow chart illustrating the Your Choice patient programme journey from registration to treatment


For more information on the Your Choice programme, download the guide for HCPs or contact a Novartis representative.  

KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1 

ECG, electrocardiogram; HCP, healthcare professional. 

  1. KISQALI (ribociclib). Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | June 2021 | 126168

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]